NCT00609856

Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

Differences in Metabolic and Cardiovascular Effects of Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Skane University Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Pioglitazone and insulin glargine are equally effective in achieving glycemic control in secondary drug failure of type 2 diabetes but the mechanisms of actions are different.

Detailed description

The present study was undertaken to assess differences in how insulin glargine vs. pioglitazone affect: * Beta-cell function as measured by proinsulin/insulin, homeostasis model assessment for insulin secretion (HOMA β-cell) and glucagon stimulated C-peptide test * Insulin sensitivity as measured by adiponectin, homeostasis model assessment for insulin resistance (HOMA-IR) and insulin tolerance test and * Surrogate markers of cardiovascular disease as measured by BNP, NT-pro BNP and plasma lipid profile as add-on therapy in patients with T2D and secondary drug failure. The patients' satisfaction with each treatment was also surveyed.

Conditions

• Type 2 Diabetes
• Secondary Drug Failure

Interventions

Type	Name	Description
DRUG	pioglitazone	tablet, 30 mg, once daily, 26 weeks
DRUG	insulin glargine	subcutaneous injection, start dose 6-10 units, once daily, 26 weeks

Timeline

• Start date: 2004-04-01
• Primary completion: 2006-12-01
• Completion: 2006-12-01
• First posted: 2008-02-07
• Last updated: 2008-02-07

Locations

1 site across 1 country: Sweden